February 21, 2025
Selpercatinib Shows 83% Response Rate in RET-Positive Cancer
Final clinical trial results demonstrate selpercatinib’s safety and efficacy in treating RET fusion-positive non-small cell lung cancer patients.
Journal of Clinical Oncology